Monte Rosa Therapeutics Advances NEK7 Program With Enhanced CNS Penetration, IND Filing Slated For 2026
GLUEJune 10, 2025
Read more →Monte Rosa Therapeutics Plans To Initiate Phase 1 Study Of MRT-8102 In Coming Weeks And Anticipates Sharing Initial Results In H1 2026
GLUEJune 10, 2025
Read more →FDA Clears IND Application For Monte Rosa Therapeutics' MRT-8102, NEK7-Directed MGD Developed To Treat Inflammatory Conditions Linked To NLRP3, IL-1β, And IL-6 Dysregulation
GLUEJune 10, 2025
Read more →Monte Rosa Therapeutics Q1 EPS $0.57 Beats $(0.30) Estimate, Sales $84.93M Beat $14.25M Estimate
GLUEMay 8, 2025
Read more →Monte Rosa's MRT-51443 Demonstrates Potent CDK2 Degradation And Delays Resistance To CDK4/6 Inhibitors In Preclinical Studies
GLUEApril 28, 2025
Read more →Wells Fargo Maintains Equal-Weight on Monte Rosa Therapeutics, Lowers Price Target to $10
GLUEMarch 21, 2025
Read more →Wedbush Maintains Outperform on Monte Rosa Therapeutics, Raises Price Target to $17
GLUEMarch 21, 2025
Read more →Novartis Partner Monte Rosa Therapeutics Touts Positive Data From Early-Stage Study Of Investigational Drug Candidate For Immune-Mediated Disorders
GLUEMonte Rosa's MRT-6160 shows promising Phase 1 results, with Novartis backing its development in a deal that could reach $2.1B in milestone payments.
March 20, 2025
Read more →Monte Rosa Therapeutics Reports Q4 Collaboration Revenue Of $60.647M, Exits Quarter With Cash And Equivalents Worth $377M
GLUEMarch 20, 2025
Read more →LifeSci Capital Initiates Coverage On Monte Rosa Therapeutics with Outperform Rating, Announces Price Target of $19
GLUEMarch 12, 2025
Read more →Monte Rosa Therapeutics Says Initial Clinical Data From Phase 1 SAD/MAD Study of VAV1-directed Molecular Glue Degrader (MGD) MRT-6160 Expected In Q1 2025
GLUEJanuary 10, 2025
Read more →Wells Fargo Downgrades Monte Rosa Therapeutics to Equal-Weight, Lowers Price Target to $11
GLUEDecember 19, 2024
Read more →Wedbush Reiterates Outperform on Monte Rosa Therapeutics, Maintains $11 Price Target
GLUEMay 22, 2024
Read more →Monte Rosa Therapeutics Will Present Preclinical Data At Digestive Disease Week 2024. Data Showed That MRT-6160-mediated Degradation Of VAV1 Inhibited Disease Progression In A T-Cell Transfer Murine Model Of Colitis
GLUEMay 21, 2024
Read more →Monte Rosa Therapeutics shares are trading lower after the company announced the pricing of a $100 million public offering.
GLUEMay 16, 2024
Read more →Monte Rosa Therapeutics Reports Pricing Of $100M Public Offering
GLUEMay 16, 2024
Read more →Credit Suisse Initiates Coverage On Monte Rosa Therapeutics with Neutral Rating, Announces Price Target of $19
GLUEApril 28, 2022
Read more →